Sii Investments Inc. WI decreased its stake in Eli Lilly and Company (NYSE:LLY) by 27.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,335 shares of the company’s stock after selling 1,291 shares during the period. Sii Investments Inc. WI’s holdings in Eli Lilly and were worth $273,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also bought and sold shares of LLY. KBC Group NV increased its position in Eli Lilly and by 117.6% during the 1st quarter. KBC Group NV now owns 757,289 shares of the company’s stock valued at $63,696,000 after purchasing an additional 409,273 shares during the period. Ronald Blue & Co. LLC grew its position in Eli Lilly and by 0.5% during the 1st quarter. Ronald Blue & Co. LLC now owns 50,597 shares of the company’s stock valued at $4,256,000 after purchasing an additional 274 shares during the last quarter. Bank of The Ozarks lifted its stake in Eli Lilly and by 24.9% during the 1st quarter. Bank of The Ozarks now owns 8,723 shares of the company’s stock valued at $734,000 after acquiring an additional 1,740 shares during the period. Stifel Financial Corp lifted its stake in Eli Lilly and by 2.6% during the 1st quarter. Stifel Financial Corp now owns 709,703 shares of the company’s stock valued at $59,657,000 after acquiring an additional 17,892 shares during the period. Finally, ARS Investment Partners LLC lifted its stake in Eli Lilly and by 7.3% during the 1st quarter. ARS Investment Partners LLC now owns 2,950 shares of the company’s stock valued at $248,000 after acquiring an additional 200 shares during the period. Hedge funds and other institutional investors own 76.43% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock in a transaction on Friday, September 29th. The stock was sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the completion of the transaction, the insider now directly owns 123,513,247 shares of the company’s stock, valued at $10,515,917,849.58. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 628,588 shares of company stock valued at $53,399,536. 0.20% of the stock is currently owned by insiders.
Eli Lilly and Company (NYSE:LLY) traded up $0.55 during trading hours on Thursday, reaching $85.87. The company had a trading volume of 4,344,910 shares, compared to its average volume of 3,673,220. The stock has a market cap of $94,220.00, a P/E ratio of 21.04, a PEG ratio of 1.89 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 12-month low of $66.39 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue was up 9.0% on a year-over-year basis. During the same period last year, the business posted $0.88 EPS. equities research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. Eli Lilly and’s dividend payout ratio is currently 99.05%.
LLY has been the topic of several recent research reports. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research note on Thursday, September 28th. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $90.25.
COPYRIGHT VIOLATION NOTICE: “Sii Investments Inc. WI Sells 1,291 Shares of Eli Lilly and Company (NYSE:LLY)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/07/eli-lilly-and-company-lly-position-decreased-by-sii-investments-inc-wi.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.